Array BioPharma’s revenue up, loss trimmed during most recent quarter
BOULDER – Array BioPharma Inc. (Nasdaq: ARRY) reported an increase in revenue and a reduction in losses during the second quarter of its fiscal year 2017 that ended Dec. 31.
The Boulder-based biotech posted revenue of $44.5 million during the most recent quarter, compared with $39.3 million for the prior quarter. The bump in revenue mainly was driven by earning a $6 million milestone from Loxo Oncology for the advancement of the cancer-fighting drug larotrectinib, and a $2.5 million milestone from Roche for the advancement of danoprevir, which fights hepatitis C.
Array still posted a loss…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!